Introduction
Gliomas are brain tumors with glial cell characteristics, and are composed of a heterogeneous mix of cells, which includes glioma stem cells. Gliomas include astrocytomas, oligodendrogliomas, ependymoma, and mixed gliomas. Gliomas account for 32% of all brain and central nervous system tumors (CNS) and 80% of all malignant brain and CNS tumors (CBTRUS, 2010) . The WHO grade III anaplastic astrocytomas (AAs) and grade IV glioblastoma multiforme (GBMs) are highly invasive tumors and make up approximately three-quarters of all gliomas (CBTRUS, 2010) . GBM is the most common and malignant form of brain tumor. GBMs make up 17% of all primary brain tumors in the United States, with an incidence of 3.17 cases per 100,000 persons per year (CBTRUS, 2010) . Although both the knowledge of glioma biology and the available resources for treatment have greatly increased over the past decade, the expected survival of malignant glioma patients remains dismal. For AA patients, the current five-year and ten-year survival rates are 27.4% and 21.3%, respectively (CBTRUS, 2010) . GBM patients have a much lower survival. The current five-year and ten-year survival rates for GBM patients are 4.5% and 2.7%, respectively (CBTRUS, 2010) . Clinical treatment for gliomas consists of a combination of surgical resection, radiotherapy and chemotherapy. Due to the infiltrative nature of GBMs, complete removal of the tumor by surgery is not possible. Following surgery, the conventional radiation dosage of up to 60 Gy is given daily in 2 Gy fractions (Buatti et al 2008) . The commonly used chemotherapy drug, temozolomide (Temodar®) , is an alkylating agent that is taken orally and readily penetrates the blood-brain barrier (Ostermann et al., 2004) . 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is an older drug that surgeons deposit in the tumor bed as dissolvable wafers (Grossman et al., 1992) . Both of these drugs alkylate DNA at multiple sites, including the O 6 position of guanine, which can result in futile cycles of DNA repair and, ultimately, cell death (Sarkaria et al., 2008) . These alkylating agents can also induce senescence (Gunther et al., 2003) . Temozolomide is administered as both concomitant and adjuvant treatments to radiotherapy. This aggressive treatment increases the two-year survival rate for GBM patients from 10.4%, with radiotherapy alone, to 26.5% (Stupp et al., 2005) . Cells that escape radiotherapy-and chemotherapy-induced cell death eventually reenter the cell cycle and contribute to local tumor recurrence. Despite advances in chemotherapy regimens, the median progression free survival in AA and GBM patients is, 15.2 months (Chamberlain et al., 2008) and 6.9 months (Stupp et al., 2005) , respectively. The median overall survival time for GBMs is 14.6 months (Stupp et al., 2005) . (A) NSC can either self-renew or differentiate to type B radial glia-like progenitor cells. They can then irreversibly differentiate to oligodendrocytes, astrocytes or neurons. (B) For GBM CSCs, the stem-like cells self-renew or differentiate to progenitor cells and then to more differentiated GFAP+ cells. Unlike the NSC, the differentiated cells may in some cases dedifferentiate.
Glioma stem cell cultures
Traditionally, glioma cells were grown in the presence of serum as adherent cultures (FIG 2) . The serum-grown cultures are tumorigenic, but unlike the invasive phenotype seen in patient gliomas, serum cultures commonly yield circumscribed tumors in intracranial xenograft models (Radaelli et al., 2009) . Gene expression in serum cultures can be drastically different from the original tumor (Lee et al., 2006) . Like neural stem cells, glioma stem cells can be grown in serum-free media with the growth factors EGF and FGF (Galli et al., 2004) . Neurosphere cultures are currently the most common method used to propagate glioma stem cells, but a new in vitro technique to grow glioma stem cells is emerging, which utilizes laminin-coated plates with serum-free media.
Neurosphere cultures
The presence of self-renewing glioma stem cells was first demonstrated in 2003. Two laboratories demonstrated that glioma tissue cultured in serum-free media supplemented with growth factors form non-adherent spheroids with an enhanced glioma stem cell population (FIG 2 and 3) . The glioma neurosphere cultures maintain genetic profiles similar to the original patients' tumors and form invasive tumors in intracranial xenografts (Ernst et al., 2009; Lee et al., 2006; Singh et al., 2004) . When plated at clonal density, each neurosphere arises from an individual glioma stem cell or transit-amplifying cell. Despite their clonal origin, neurospheres are heterogeneous aggregates that consist of glioma stem cells, transitamplifying cells, and more differentiated glioma cells. The percentage of neurosphereinitiating can vary greatly among glioma cultures, and neurosphere formation has been demonstrated to increase when neural stem cells are transformed . The majority of cells in a neurosphere are transit-amplifying cells (Ahmed, 2009) . When these neurosphere cultures are dissociated to single cells, a small percentage of the cells can form secondary and tertiary neurospheres for many passages Reynolds and Weiss, 1996) . Glioma stem cells have a high capacity to proliferate and self-renew and robustly form secondary neurospheres. When exposed to fetal bovine serum, neurosphere cells differentiate down the lineage of the parent tumor (Singh et al., 2003) . Therefore, gliomas preferentially differentiate to astrocytes, but multilineage differentiation can occasionally be observed with neuronal lineages, and some abnormal cells with mixed phenotypes. It should be noted that these lineages are based on markers but not function. For example, the crucial test for a neuron is an action potential, which is not tested. Also, a significant difference between neural stem cell and glioma stem cell cultures is that serum differentiation of normal neural stem cells is permanent (Lee et al., 2006) , while glioma lines established as serum cultures can be converted to neurospheres in serum-free media Qiang et al., 2009) . Neurosphere cultures express known neural stem cell genes, such as Musashi-1, Sox2, and Bmi-1 (Hemmati et al., 2003) (FIG 2) . Stem cell membrane markers, such as CD133 and CD15, are also expressed in neurosphere cultures and are discussed in further detail in subsequent sections. Using neurosphere assays to analyze glioma stem cell content can be complicated. As mentioned above, both glioma stem cells and transit amplifying cells are capable of neurosphere formation. In addition, neurospheres aggregate and fuse with one another when the cells are plated at higher densities (Singec et al., 2006) . Therefore, the number of neurospheres is a measure of the number of both glioma stem cells and transit amplifying cells and is accurate only when the cells are plated at low densities. Despite these concerns, neurosphere cultures remain a valuable tool in glioma stem cell research.
Laminin-coated cultures
A key aspect of the neurosphere culture system is that the serum-free, defined media maintains the glioma stem cell phenotype of the cells. However, in addition to glioma stem cells, neurospheres contain more differentiated progeny and regions of cell death. This is thought to be caused by the condensed structure of the neurosphere, which hinders the diffusion of the growth factors to the innermost cells ). Differentiation and cell death could be limited if glioma cultures were grown in a monolayer in the presence of serum-free, defined medium. This can be achieved by culturing glioma samples in the serum-free, defined medium on laminin-coated cell culture plates (Pollard et al., 2009) . When cultured on laminin-coated plates, cells that would normally form neurospheres grow as an adherent culture, which allows all of the cells equal access to growth factors. The adherent glioma stem cell lines are less heterogeneous than neurosphere cultures, and almost all of the cells express glioma stem cell genes, such as Sox2, Nestin, CD133 and CD44 (FIG 2) . There is minimal expression of differentiation markers. The adherent, laminin cultures are capable of tumor formation when as few as 100 cells were intracranially injected into immunocompromised mice, demonstrating the high percentage of tumor-initiating glioma stem cells. An additional benefit of the laminin glioma stem cell culture system is that all gliomas with good cell viability formed long-term cell lines. 
Glioma stem cell markers
Markers are commonly used to identify and isolate different cells types. The most commonly used cell surface markers for glioma stem cells are CD133, CD15, and A2B5. New, less characterized markers are also being tested for glioma stem cells. When cells are isolated from tumors or glioma cultures with these markers, their stem cell characteristics can be analyzed based on stem cell gene expression, multilineage differentiation capabilities and neurosphere formation; however, tumor formation in xenograft models is the most important method to confirm that a marker identifies the glioma stem cell population. Despite many successes using cell surface markers such as CD133, it has become increasingly clear that individual gliomas are very heterogeneous and in addition, tumors vary greatly from patient to patient (Phillips et al., 2006) . There is currently no universally accepted collection of markers for isolation of a pure population of glioma stem cells (Gilbert and Ross, 2009 ). In addition, to complicate the glioma stem cell field, some of the markers used appear to only be relevant when the cells are isolated directly from the tumor tissue. The heterogeneity of malignant gliomas may make it difficult to use a single set of markers to identify and purify glioma stem cells in every glioma.
CD133
CD133 (also known as Prominin-1) was first discovered as a cell surface marker for hematopoietic stem cells (Miraglia et al., 1997) . In the human fetal brain, CD133 is a marker for neural stem cells (Uchida et al., 2000) . CD133 expression has also been observed in intermediate radial glial cells in the early postnatal brain, and in ependymal cells in the adult brain (Coskun et al., 2008; Pfenninger et al., 2007) . Neurogenic astrocytes in the neural stem cell region of the subventricular zone do not express CD133. Despite its inconsistent expression in adult neural stem cells, CD133 has been used to isolate populations of cancer stem cells from multiple types of brain tumors (Singh et al., 2003; Singh et al., 2004) . Expression of CD133 in anaplastic astrocytomas and glioblastoma multiforme varies among patients and tumor grade, with reports of 0 -64% (Ogden et al., 2008; Singh et al., 2003; Singh et al., 2004; Son et al., 2009) . CD133 + cells from gliomas are capable of multilineage differentiation and have a high capacity for neurosphere formation. The corresponding CD133 -cells did not proliferate in neurosphere cultures. Furthermore, CD133 + glioma cells express significantly higher levels of neural stem cell genes, such as nestin, Msi-1, maternal embryonic leucine zipper kinase (MELK) and CXCR4 (Liu et al., 2006) . These data support the stem cell genotype of CD133 + glioma stem cells and suggests that similar signaling pathways may be involved in normal neural stem cells and brain cancers. The gold standard to classify a cell as a glioma stem cell is that it can form a xenograft tumor that is capable of serial transplantations in immunodeficient mice. CD133 + glioma cells have an increased capacity for tumor initiation after intracranial transplantation into mice (Singh et al., 2004) . Injection of only 100 CD133 + cells results in tumors capable of serial transplantation, while 100,000 CD133 -injected cells do not form tumors. It is important to note that the laboratories that have had the most success studying glioma stem cells based on CD133 expression have isolated the cells from primary patient tissue and fresh xenograft samples (Bao et al., 2006a; Singh et al., 2004; Wang et al., 2010) . CD133 knockout mice manifest with a progressive photoreceptor degeneration that leads to total vision loss (Zacchigna et al., 2009) . It is surprising that with the wide range of expression of cells expressing CD133 throughout the body and its link to stem cells that there are not more developmental defects. However, the authors suggest that further studies to characterize the mice under stressed conditions may uncover other defects in the CD133 -/-mouse model. An additional explanation is that the family member Prominin-2, which may provide redundant functions, is co-expressed in most tissues, excluding the retina (Fargeas et al., 2003) . Other than its involvement in retinal development, little is known about CD133 function. Recent reports demonstrate that its expression may be cell cycledependent (Beier et al., 2007; Jaksch et al., 2008) or regulated by hypoxic environments (Griguer et al., 2008) . In addition, in the small intestines and the prostate, CD133 marks both the transit-amplifying population and the stem cells (Grey et al., 2009; Snippert et al., 2009) . These data imply that CD133 may only identify a subset of glioma stem cells that are actively proliferating, and CD133 + populations may include progenitor cells. A rising concern for CD133 as a glioma stem cell marker is that up to 40% of freshly isolated glioma tumors do not express CD133 (Son et al., 2009) . Tumors negative for CD133 expression still included cells with stem cell-like properties of self-renewal, multilineage differentiation, and xenograft tumor formation (Beier et al., 2007) . Differences in CD133 expression among gliomas may be result from the origin of the tumor-initiating cell (Lottaz et al., 2010 Ogden et al., state that the A2B5 data do not diminish the utility of CD133 as a glioma stem cell marker, but rather demonstrates a broader population of cells capable of tumor formation. Contrarily, the very high percentage of A2B5 + cells brings up the question of the rarity of the tumor initiating, cancer stem cell in some tissues. It will be interesting to see in the future if additional markers can identify a purer subset of glioma stem cells from the A2B5 + population, or if like observed in melanomas (Quintana et al., 2008) , the glioma stem cell population could make up a very large percent of the tumor.
CD15
CD15 (also known as SSEA-1 and Lewis-X Antigen) is a carbohydrate adhesion molecule associated with glycolipids and glycoproteins. CD15 expression has been shown on neural stem cells derived from human embryonic stem cells and embryonic neural stem cells (Barraud et al., 2007; Pruszak et al., 2007) . In freshly isolated GBMs, distinct populations of CD15 varied from 2.4 -70% (Son et al., 2009 ). CD15 + cells had increased expression of stem cell genes, such as Sox2 and Bmi1, and were capable of self-renewal and multilineage differentiation. CD15 + cells also form neurospheres in serum-free, defined medium, while CD15 -cells had minimal neurosphere formation (Mao et al., 2009) . A large percent of CD133 + cells co-expressed CD15, but there was also a unique population of CD15 + /CD133 -cells. Additionally, tumors negative for CD133 possessed CD15 + cells (Son et al., 2009) . CD15 + cells isolated from GBMs were highly tumorigenic, while SSEA-1 -cells displayed limited tumor formation in mouse intracranial xenografts. Importantly, 23 out of 24 primary GBMs analyzed contained a subpopulation of CD15 + cells. Cells expressing CD15 that were isolated from CD15 + /CD133 -neurospheres were capable of forming intracranial tumors in mice (Mao et al., 2009 ). These results together suggest that CD15 is a useful marker for both normal neural stem cells and glioma stem cells, and may identify new CD133 -glioma stem cells.
New markers: Podoplanin and Integrin Alpha 6
There are two new promising cancer stem cell markers. The first, podoplanin, is a mucintype transmembrane glycoprotein. It is over expressed in a variety of cancers, including squamous cell carcinomas, colorectal carcinomas and brain tumors (Cortez et al., 2010) . For glioblastomas, podoplanin is expressed both in tumors and primary neurospheres in culture (Christensen Neurosurgery 2010). Elevated levels of podoplanin are associated with invasiveness, but the mechanism is not known (Cortez et al., 2010; Shen et al., 2010) . The second new marker, integrin alpha 6, plays an important role in normal neural stem cells . Integrin alpha 6 binds laminin and plays a role in maintaining the stem cells in the subventricular zone. Lathia et al. provided strong evidence that integrin alpha 6-positive cells have cancer stem cell characteristics. These cells are more proliferative and potent for neurosphere and tumor formation.
Glioma stem cell protection mechanisms

Immunosuppression
The capacity to evade tumor surveillance by the immune system may be a key step in the development of cancer and may involve cancer stem cells (Jaiswal et al., 2010) . The immune responses to GBMs can be potent (Di Tomaso et al., 2010; Lichtor and Glick, 2003) . For example, dendritic cells loaded with glioma cancer stem cells and then injected subcutaneously substantially suppress intracranial tumor growth (Pellegatta et al., 2006) . Ironically, antigens associated with glioma cancer stem cells may activate the immune system, and by an independent mechanism, GBM cells may suppress the immune system. GBMs secrete immunosuppressive factors, including TGF-β, VEGF, PGE 2 , B7-H1, galectin-3 and CCL-2 . Conditioned medium from GBMs inhibits T-cell proliferation and induces T regulatory cells (Tregs), which can suppress the functions of T-cells, B-cells, dendritic cells, monocytes, macrophages and natural killer (NK) cells (Humphries et al., 2010; Wei et al., 2010) . Di Tomaso and colleagues (2010) found that glioma stem cells were particularly effective for inhibition of T-cell proliferation. In addition, phagocytic cells can play an important role in clearing tumor cells (Jaiswal et al., 2010) , and high-grade GBMs may include up to 30% microglia cells (Hanisch and Kettenmann, 2007) . Rodrigues et al. (2010) concluded that GBMs suppress activation of microglial cells, and the GBMsuppressed microglial cells, in turn, suppress T-cell activity by secreting immunosuppressive factors, IL-10 and Fas-ligand. The multiple immunosuppressive mechanisms are consistent with our view that interactions with the immune system play a major role in the development of GBMs. It has been suggested that cancer is a result of malignant cells evading the body's immune system. Glioma stem cells disrupt tumor immunosurveillance and result in both ineffective adaptive and innate immune responses. This is another mechanism that glioma stem cells help protect the tumor, which results in high rates of tumor recurrence and patient death. Theoretically, targeting the glioma stem cell-induced immunosuppression can enhance the survival of glioma patients.
Chemoresistance and radioresistance
By several mechanisms, the stem cell character of glioma stem cells may also contribute to resistance of tumor cells to therapy (FIG 4) . First, normal stem cells can assume a quiescent state that is regulated by the stem cell niche. Cells that are not proliferating or stop after DNA damage have an enhanced chance of survival. Several groups have proposed that cancer stem cells readily assume a quiescent state and later, following DNA repair, repopulate the tumor (Mellor et al., 2005; Scopelliti et al., 2009) . Our laboratory recently demonstrated that even low doses of temozolomide can induce quiescence followed by a robust recovery of the culture (Mihaliak et al., 2010) . The neurosphere recovery assay provides a quantitative cell culture assay to test the efficacy of drug combinations at inhibiting repopulation. We demonstrated that temozolomide drastically diminished initial neurosphere formation in many glioma cultures; however, these cultures eventually recovered and formed a robust number of secondary neurospheres (Mihaliak et al., 2010) . The ability of temozolomide treated neurospheres to recover and repopulate the culture suggests that some cells undergo a transient cell cycle arrest, allowing them to evade cell death and eventually resume proliferation. CD133 + cells were more resistant to multiple chemotherapeutic agents, including temozolomide, compared to CD133 -cells from the same primary glioma cultures (Liu et al., 2006) . Glioma cells that survived after 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment expressed high levels of CD133 + and retained their tumorigenic potential in intracranial mouse xenografts (Kang and Kang, 2007) . In addition, ionizing radiation enriched the CD133 + population of human glioma cultures Fig. 4 . CSCs and cancer therapy. The CSC model helps us to understand why current cancer therapies fail and aids development of novel, more effective approaches. (A) It has been proposed that CSCs (red circles) are resistant to current cancer therapy, survive even the most rigorous therapies that kill the more differentiated cells (blue circles) and allow tumor repopulation. (B) One of the most appealing aspects of the CSC model is that therapies directed against CSCs might eliminate the cells with long-term self-renewal potential, and the more differentiated cells, which lack self-renewal potential, will eventually cease cell proliferation and die. (C) In a more recent CSC model (Chen et al and Fig. 1) , some differentiated cells can revert to CSCs. If this model is correct, then a therapy exclusively directed against the CSCs would allow creation of new CSCs and repopulation of the tumor. (D) A new approach that takes into account dedifferentiation is to combine CSC directed therapy to decrease the number of the most important cells and a nonspecific therapy to clear the differentiated cells and, thereby, reduce the chance of dedifferentiation.
derived from xenografts and GBM patient samples (Bao et al., 2006a) . Based on these data, CD133 + populations were more resistant to ionizing radiation in colony formation assays compared to the corresponding CD133 -populations. On the other hand, it has been shown that number of CD133 + glioma cells can decrease or show no significant change after chemotherapy treatment (Beier et al., 2008; Mihaliak et al., 2010) . There may be several explanations for these inconsistent results. First, these differences could support the issue that CD133 is not a universal stem cell marker for all gliomas. Second, they could be due to different sources of the glioma stem cells, for example neurosphere cultures, versus xenografts, versus fresh patient tissue. Finally, the disparate results may be on account of the time points that the data are analyzed after treatments and the concentrations of the drug treatments. Mihaliak et al. (2010) demonstrated that the chemotherapy treatments induced a cell cycle arrest in the neurosphere initiating cells at clinically relevant doses, but required higher concentrations to induce cell death in the bulk of the cells. The drug concentrations to achieve this cell cycle arrest varied both by cell line and by the chemotherapy drug used. Therefore, depending on the time point that the culture is analyzed, the ratios of glioma stem cells to the total bulk cells can greatly vary. Another feature that normal stem cells and glioma stem cells share is expression of drug efflux pumps. Adenosine triphosphate-binding cassette (ABC) pumps, ABCG2 and Pglycoprotein are expressed on glioma stem cells and are responsible for efflux of the fluorescent Hoechst 33342 dye, leading to the side population, which is enriched in glioma stem cells (Lu and Shervington, 2008) . However, in a model system, ABCG2-positive andnegative cells showed no difference in tumor formation in mice (Patrawala et al., 2005) . The ABC transporters are often proposed to enhance survival of glioma stem cells by efflux of chemotherapy drugs, but temozolomide is not a substrate for ABCG2, and expression of ABCG2 did not provide resistance to temozolomide treatment (Bleau et al., 2009) . Glioma stem cells express a variety of proteins that promote survival following cancer treatment. The major drug resistance protein, MGMT, and anti-apoptotic genes such as FLIP, BCL-2, BCL-XL, cIAP1 and survivin were upregulated in CD133+ glioma cells (Ghods et al., 2007; Liu et al., 2006) . Ionizing radiation resulted in a greater activation of DNA checkpoint responses in CD133 + cells by phosphorylation of Rad15, ATM, Chk1 and Chk2 than in the autologous CD133 -cells (Bao et al., 2006a) . This indicates that CD133 + glioma stem cells resistance to radiotherapy is partially due to enhanced DNA repair. As a result, pathways related to glioma stem cell functions and resistance to therapy will be promising targets for novel therapies.
Therapeutic targets
Current glioma treatments target the bulk of the tumor, but are insufficient (FIG 4) . Since tumor recurrence is attributed to glioma stem cell therapy resistance, treatments that directly target glioma stem cells could yield long-term cures. Many have hypothesized that once the glioma stem cells have been eliminated, the bulk tumor would not be able to sustain itself and would disseminate; however, in gliomas, it has been hypothesized that some differentiated tumor cells have the ability to revert to stem cell-like cells (FIG 2 and 4 ) Gupta et al., 2009) . The most affective treatments would consist of radiation and chemotherapy against the bulk tumor combined with direct-targeted against the glioma stem cell population. Signaling pathways associated with either mechanisms of resistance or pathways required for the function of glioma stem cells could be targeted to enhance therapy.
Notch pathway
The Notch signaling pathway is an important regulator in normal development, adult stem cell maintenance, and tumorigenesis in multiple organs, including the brain (Koch and Radtke, 2007) . Notch signaling is a promising pathway to target glioma cells, since the Notch receptors, their ligands, and downstream targets are commonly over-expressed in glioma tissue and cell lines (Fischer and Gessler, 2007; Kanamori et al., 2007; Shih and Holland, 2006) . The Notch gene mutation was first discovered in flies with 'notched' wings (Radtke and Raj, 2003) . There are four mammalian Notch receptors (Notch1 through 4) and five membrane-associated ligands in the Delta and Jagged families. Activation of the Notch pathway through cell-cell interactions initiates a signaling cascade (Pannuti et al., 2010) . When a ligand binds to a Notch receptor, the metalloprotease ADAM protein cleaves the extracellular domain of Notch, which initiates intracellular cleavage by the gamma secretase complex (Stockhausen et al., 2010) . The gamma-secretase cleavage releases the Notch intracellular domain (NICD), which facilitates its translocation into the nucleus (Miele, 2006) . The NICD forms a complex with CSL (CBF1/Suppressor of Hairless/Lag1) and drives transcription of downstream targets, including members of the Hairy enhancer of split (Hes) and Hes-related repressor protein (HERP/Hey) families (Iso et al., 2003) , cyclin D (Ronchini and Capobianco, 2001) , and c-myc (Sharma et al., 2006) , and p21 ). Notch signaling is a promising target for directed therapy since it can be blocked at multiple stages of the pathway (Rizzo et al., 2008) . The most common approach to block the Notch pathway in basic research, and in Phase I and Phase II clinical trials, is via small molecule inhibitors of gamma-secretase (Miele, 2006) . Administration of gamma-secretase inhibitors blocks the cleavage of the Notch receptor, and the intracellular domain remains bound to the cellular membrane, halting the Notch signaling cascade. Treatment with gammasecretase inhibitors can lead to gastrointestinal tract cytotoxicity (Barten et al., 2006) ; however, intermittent treatment schedules can to diminish these side effects (Rizzo et al., 2008) . Inhibiting the Notch signaling pathway can target the glioma stem cell population. Notch signaling directly activates transcription of the stem cell marker, nestin (Shih and Holland, 2006) . Expression of nestin in a murine K-ras glioma model was demonstrated to correlate specifically with Notch activation. Likewise, knockdown of Notch by shRNAs or γ-secretase inhibitors decreased the expression of stem cell markers nestin and CD133 and decreased neurosphere formation (Jeon et al., 2008) . Inhibiting the Notch pathway through gammasecretase inhibitors or shRNAs against Notch1, both led to suppression of cell growth and increased differentiation (Kanamori et al., 2007) . In glioma cultures, GSI treatment suppressed cell growth and decreased neurosphere formation and tumor growth of CD133+ cells (Fan et al., 2010) . Correspondingly, increased Notch signaling enhanced glioma cell survival (Purow et al., 2005) . Gamma-secretase inhibitors were also shown to sensitize glioma neurosphere cultures to radiation, thereby, increasing the efficacy of radiotherapy . The combination of temozolomide chemotherapy with gamma-secretase inhibitor treatment also decreased neurosphere formation and inhibited neurosphere recovery . Ex vivo treatment of glioma xenografts with temozolomide and gamma-secretase inhibitors extended tumor latency and survival, and in vivo temozolomide and gamma-secretase inhibitor treatment blocked tumor progression in 50% of mice with pre-existing tumors. These results suggest that an active Notch pathway maintains the glioma stem cell population and provides protection from chemotherapy and radiation treatments. Therefore, therapies targeting Notch receptors, ligands and downstream targets may enhance current glioma treatments.
Hedgehog pathway
The Hedgehog gene was first discovered in flies due to a mutation in the gene that caused Drosophila larvae to possess hedgehog-like spines (Mohler, 1988) . The Hedgehog pathway is vital for normal brain development and neural stem cell survival (Ahn and Joyner, 2005; Wechsler-Reya and Scott, 1999) . There are three mammalian Hedgehog homologues, the most studied being Sonic Hedgehog (Marti and Bovolenta, 2002) . Sonic Hedgehog is the ligand that activates the pathway, and when it is not present, the Patched receptor inhibits the Smoothed membrane-bound protein. When the ligand binds to Patched, Smoothened is activated, which in turn activates the downstream targets of the Gli transcription factors (Gli1 through 3), which were first discovered in human glioma (Kinzler et al., 1987) . Glioma cell lines and primary glioma tissues commonly express Patched, Sonic Hedgehog and Gli (Clement et al., 2007; Dahmane et al., 2001) . The Hedgehog pathway can be blocked with steroidal alkaloid, Smoothened inhibitor, cyclopamine (Chen et al., 2002) . Cyclopamine is a naturally occurring compound that was discovered in a fascinating manner. The compound was named after a group of lambs that were born with one eye in the center of their forehead, imitating a Cyclops (Binns et al., 1964) . The parental sheep had grazed on wild corn lilies that produced the cyclopamine, leading to incomplete developmental growth, which was later attributed to the inhibition of the Hedgehog pathway (Cooper et al., 1998) . The Hedgehog pathway plays an important role in glioma tumorigenesis. Treatment of neurosphere cultures with cyclopamine, inhibited sphere formation, and enhanced radiation treatment (Bar et al., 2007) and temozolomide chemotherapy (Clement et al., 2007) . Cyclopamine treatment also depleted the number of nestin + cells, CD133 + cells, and the Hoechst 33342 side population, suggesting that inhibition of the Hedgehog pathway decreases the glioma stem cells (Bar et al., 2007) . In vivo cyclopamine treatment reduced tumor volume intracranial neurosphere xenografts (Clement et al., 2007) . Active Hedgehog signaling in glioma cultures increased survival after chemotherapy and Gli1 expression in patient tissues is associated with glioma recurrence after chemotherapy (Cui et al., 2010) . Treatment with cyclopamine to block the Hedgehog pathway increased the cytotoxicity in chemotherapy treated cultures. These data suggest that inhibiting the Hedgehog pathway enhances the sensitivity to current GBM radiation and chemotherapy treatments by targeting the glioma stem cell population.
VEGF, Angiogenesis, and Bevacizumab
Aberrant, inordinate angiogenesis is a hallmark of malignant gliomas. This abnormal angiogenesis supports tumor growth and has been considered a target for glioma therapy. Glioma stem cells have been associated with a vascular stem cell niche. Nestin + and CD133 + brain tumor cells were consistently located in the proximity of the tumor's vascular system (Calabrese et al., 2007) . It has been demonstrated that xenografts from CD133 + glioma cells form highly vascular tumors compared to xenografts from CD133 -cells (Bao et al., 2006b ). In addition, secretion of vascular endothelial growth factor (VEGF) from CD133 + cells was consistently upregulated. The VEGF family and the tyrosine kinase VEGF receptors are important in glioma angiogenesis. When VEGF binds to the receptor, the MAP kinase pathway, the Raf-MEK-Erk pathway, and the PI3K-Akt pathway are activated (Korpanty et al., 2010) . The VEGF pathway can be blocked with the FDA-approved bevacizumab (Avastin™), a neutralizing monoclonal antibody against free VEGF. Bevacizumab in vivo treatment inhibited the growth of subcutaneous and intracranial CD133 + glioma xenografts (Bao et al., 2006b ). Anti-angiogenesis treatments have been demonstrated to decrease glioma growth. The vascular niche may regulate glioma stem cell proliferation and provide a protective shield for glioma stem cells against treatment. Therefore, therapies targeting the fundamental angiogenic factors could simultaneously be a treatment against glioma stem cells. Early results from clinical trials with bevacizumab have proved hopeful (Desjardins et al., 2008; Friedman et al., 2009; Kreisl et al., 2009) . Although there have been only minimal, well-tolerated side effects (Rahman et al., 2010) , the gliomas that recur after bevacizumab treatment are diffuse tumors that are unusually distant from the primary glioma (Zuniga et al., 2009 ). Current glioma therapies may fail to cure patients because glioma stem cells possess mechanisms to evade treatments and enhance survival. The remaining cells promote tumor regrowth. To circumvent the many protective features of glioma stem cells, such as chemoresistance, radioresistance, and immunosuppression, therapies for glioma stem cells must target the vital pathways for glioma stem cell function and their vascular niche. Combining drugs that target glioma stem cells with surgery, current chemotherapies, and radiation will enhance the overall survival for glioma treatment and decrease tumor recurrence.
Summary and future directions of the glioma stem cell field
In our view, the cancer stem cell model has had a positive effect on cancer research, leading to a close examination of tumor cell heterogeneity brought about by differentiation, as well as other causes (Shackleton et al., 2009) . However, the model has also led to a series of new questions and controversies. First, is this model applicable to all gliomas? Ogden et al. (2008) found that CD133 only identifies cancer stem cells in a small subset of GBMs (1/6 tumors). In addition, there are CD133 -GBMs that are still aggressive tumors (Beier et al., 2007) . If CD133 does not select for cancer stem cells in every glioma, is there a better, more universal marker available? As noted in this review, other markers are being tested, but right now there is no agreement in the field. Second, perhaps, the markers are not working because the cancer stem cell model is too simple. Chen et al. (2010) proposed that there is no single marker signature for the cancer stem cell. Instead, they proposed that there are at least three cell types with varying degrees of stemness. An intriguing aspect of this model is the hierarchy. In most models, the cancer stem cells irreversibly differentiate to cells with less potential for self-renewal and tumor formation. In some cases, the more differentiated cells may be able to dedifferentiate back to a stem-like cells Gupta et al., 2009) . Third, what is the best source of cells for glioma stem cell studies, and what is the best method to culture these cells? Some of the most thorough studies utilize cells shortly after removal of tumors from patients or immunodeficient mice and not cells maintained in culture for many passages (Bao et al., 2006a; Singh et al., 2004; Wang et al., 2010) . To enhance stem cell properties, glioma cells are commonly grown as neurospheres in defined medium. A newer method is to grow adherent cells on laminin-coated plastic (Pollard et al., 2009) , and there are critics and advocates for this method (Reynolds and Vescovi, 2009; Woolard and Fine, 2009 ). Fourth, the most important question for the clinic is whether the glioma stem cells are the cells in the tumor that are most resistant to therapy and hence, lead to repopulation of the tumor? The disagreements on this point may relate to the preceding questions and inconsistencies about glioma stem cell markers and methods to culture these cells. Until we agree on what is a glioma stem cell and how to prepare them, disagreements between different groups and studies will continue. Given this complexity, what is the best strategy for cancer therapy? Advocates for the cancer stem cell model suggested that therapy be directed against glioma stem cells, and the remainder of the tumor cells will eventually wither away (Cheng et al., 2010) . However, since it has been proposed that the differentiated cells can dedifferentiate into stem cell-like cancer cells Gupta et al., 2009) , only targeting the glioma stem cells could lead to tumor recurrence. This suggests that to have successful long-term cures of gliomas, combined therapy targeting both the bulk of the tumor and the glioma stem cells will be necessary (Cheng et al., 2010) . Promising research has recently taken this novel approach combining a directed therapy against the Notch pathway either with chemotherapy or radiotherapy ). These studies demonstrate the proof-of-principle for the enhancement of current therapies with new cancer stem cell directed drugs. The glioma stem cell field is continuously growing and it will be exciting to see these translational studies tested in the clinical setting. 
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